Tags

Type your tag names separated by a space and hit enter

Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks.
Cephalalgia. 2009 Nov; 29(11):1133-48.C

Abstract

The efficacy of a 6-day regimen of frovatriptan for menstrual migraine (MM; attacks starting on day -2 to +3 of menses) prevention in women with difficult-to-treat MM was assessed. Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled, parallel-group trial. Women were randomized to double-blind treatment for three perimenstrual periods (PMPs) with either frovatriptan 2.5 mg (q.d. or b.i.d.) or placebo initiated 2 days before anticipated MM. The efficacy analysis included 410 women with 85% completing three double-blind PMPs. The mean number of headache-free PMPs was 0.92 with frovatriptan b.i.d., 0.69 with frovatriptan q.d. and 0.42 with placebo [P < 0.001 (b.i.d.) and P < 0.02 (q.d.) vs. placebo]. When migraine occurred, severity was reduced with frovatriptan q.d. (P < 0.001) and b.i.d. (P < 0.001) vs. placebo. Both frovatriptan regimens were well tolerated. In women with difficult-to-treat MM, a 6-day regimen of frovatriptan significantly reduced MM incidence and severity.

Authors+Show Affiliations

Nashville Neuroscience Group, PC, Vanderbilt University School of Medicine, Nashville, TN, USA 37203. jbrandes@nashvilleneuroscience.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Historical Article
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19811503

Citation

Brandes, J L., et al. "Short-term Frovatriptan for the Prevention of Difficult-to-treat Menstrual Migraine Attacks." Cephalalgia : an International Journal of Headache, vol. 29, no. 11, 2009, pp. 1133-48.
Brandes JL, Poole Ac, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29(11):1133-48.
Brandes, J. L., Poole, A. c., Kallela, M., Schreiber, C. P., MacGregor, E. A., Silberstein, S. D., Tobin, J., & Shaw, R. (2009). Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia : an International Journal of Headache, 29(11), 1133-48. https://doi.org/10.1111/j.1468-2982.2009.01840.x
Brandes JL, et al. Short-term Frovatriptan for the Prevention of Difficult-to-treat Menstrual Migraine Attacks. Cephalalgia. 2009;29(11):1133-48. PubMed PMID: 19811503.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. AU - Brandes,J L, AU - Poole,A c, AU - Kallela,M, AU - Schreiber,C P, AU - MacGregor,E A, AU - Silberstein,S D, AU - Tobin,J, AU - Shaw,R, PY - 2009/10/9/entrez PY - 2009/10/9/pubmed PY - 2009/12/24/medline SP - 1133 EP - 48 JF - Cephalalgia : an international journal of headache JO - Cephalalgia VL - 29 IS - 11 N2 - The efficacy of a 6-day regimen of frovatriptan for menstrual migraine (MM; attacks starting on day -2 to +3 of menses) prevention in women with difficult-to-treat MM was assessed. Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled, parallel-group trial. Women were randomized to double-blind treatment for three perimenstrual periods (PMPs) with either frovatriptan 2.5 mg (q.d. or b.i.d.) or placebo initiated 2 days before anticipated MM. The efficacy analysis included 410 women with 85% completing three double-blind PMPs. The mean number of headache-free PMPs was 0.92 with frovatriptan b.i.d., 0.69 with frovatriptan q.d. and 0.42 with placebo [P < 0.001 (b.i.d.) and P < 0.02 (q.d.) vs. placebo]. When migraine occurred, severity was reduced with frovatriptan q.d. (P < 0.001) and b.i.d. (P < 0.001) vs. placebo. Both frovatriptan regimens were well tolerated. In women with difficult-to-treat MM, a 6-day regimen of frovatriptan significantly reduced MM incidence and severity. SN - 1468-2982 UR - https://www.unboundmedicine.com/medline/citation/19811503/Short_term_frovatriptan_for_the_prevention_of_difficult_to_treat_menstrual_migraine_attacks_ L2 - https://journals.sagepub.com/doi/10.1111/j.1468-2982.2009.01840.x?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -